Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

European Research Council grant · Running

NeuroDegRNA-Tx Harnessing cellular resilience through RNA therapeutics in neurodegeneration

Coordinator
The Chancellor Masters and Scholars of the University of Cambridge, United Kingdom
Runs
1 July 2026 to 31 December 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101290450

What the project is doing

In the project's own words, from its summary on CORDIS.

NeuroDegRNA-Tx aims to develop and validate a novel mRNA-based therapeutic strategy that enhances intrinsic cellular resilience to treat Alzheimer’s disease (AD). While most current treatments focus on removing the causative protein aggregates, the NeuroDegRNA-Tx approach leverages our recent discovery of a novel stress-resilience mechanism, which we named as SITA (Stress-Induced Transcriptional Attenuation). SITA enables cells to suppress non-essential transcription during the stress of protein misfolding, sparing cellular resources for preserving protein homeostasis.

Our data showed that SITA deficiency accelerates disease progression in mouse models of AD. Using genome-wide CRISPR screens, we identified several SITA enhancers (SITAe) as promising therapeutic targets. NeuroDegRNA-Tx will test whether mRNA delivery of SITAe in diseased brains can restore SITA function and reduce disease phenotypes in established mouse models of AD. Using lipid nanoparticle (LNP)-encapsulated mRNA, we will validate hippocampal delivery, assess protein expression, and evaluate behavioural improvements.

Single-cell RNA sequencing will confirm target engagement and cell-type-specificity while ensuring therapeutic safety. A lead SITAe candidate will be selected based on efficacy and safety. Commercially, the project will generate critical preclinical data to support patenting, derisk translational development and prepare for follow-up funding through schemes such as EIC Transition. Stakeholder involvement includes academic leaders in RNA therapeutics, neurodegeneration and cellular stress biology, as well as Cambridge Enterprise for IP and commercial strategy.

By combining breakthrough mechanistic insights with the enormous potential of RNA-based drugs, NeuroDegRNA-Tx will shift the treatment paradigm from elimination of protein aggregates to improvement in cellular resilience. The project will pave a novel therapeutic avenue in neurodegeneration using mRNA therapeutics.

Topics

Who is involved

OrganisationCityCountryRole
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI